Cancer care group Helsinn has put $50m into a corporate venturing unit called Helsinn Investment Fund that will target early-stage companies.
Switzerland-based, cancer-focused healthcare group Helsinn committed $50m to an early-stage investment fund called Helsinn Investment Fund yesterday.
Helsinn Investment Fund will target startups developing oncology treatments and diagnostics technology, cancer supportive care, and treatments for dermatology conditions, metabolic and gastrointestinal disorders covering biotech, therapeutics, medical devices and food supplements.
The fund will make its initial investments over a three-year period and will take part in follow-on rounds in the subsequent five. It plans to build a portfolio of 10 to…
